ClinicalTrials.gg
RecruitingNCT07057674Updated Jul 10, 2025

A Study of HS-20094 in Overweight or Obese Participants

A Phase 1 interventional study of HS-20094 AI pen; and HS-20094 MDV pen in Overweight or Obesity, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-10.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
212th of 502
144 · median 120
Started
2025
with 113 others
Phase 1
93 of 600
29 open now
Primary completion
2026-02
later than 56 of 280 live
Registered
368th of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 212th largest by planned enrollment of the 502 interventional ones that give a count, is one of 114 that started in 2025, is one of 93 in phase 1, reaches primary completion later than 56 of the 280 other live ones, and was the 368th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, parallel clinical study to evaluate the bioequivalence of the HS-20094 MDV pen and AI pen in overweight or obese subjects.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 144 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand the procedures and methods of this study, willing to strictly adhere to the clinical study protocol to complete this study, and voluntarily sign the form;
  2. Adult male or female participants (aged 18-65 years (inclusive), calculated based on the date of signing the informed consent form);
  3. (BMI) ≥24.0 kg/m2 (BMI = weight (kg) / height2 (m2)); body weigh ≥45 kg for female participants and ≥50 kg for male participants.
  4. Self-reported diet/exercise control alone for at least 12 weeks prior to screening, with a weight change of ≤5% in the past 12 weeks (based on self-report); calculation formula for weight change: (highest weight - lowest weight within 12 weeks prior to screening) ∕ highest weight * 100%;
  5. Agree to take effective measures from the signing of the informed consent form until 8 weeks after the last dose, and have no plans for conception or sperm/egg donation during this period (only non-drug contraceptive measures are permitted during the study).

Exclusion criteria

Exclusion Criteria:

Participants with any of the following examination abnormalities at screening:

  1. Laboratory test results meet any of the following criteria (if there is a clear reason for retesting, one re-examination can be conducted within the time window of the screening period, and the results of this re-examination will be used as the basis for screening):

    • HemoglobinA1c () ≥6.5% or fasting plasma glucose ≥7.0 mmol/L;

      • Fasting plasma glucose \<2.8 mmol/L;

        • > 3 × , or aspartate aminotransferase > 3 × ULN, or total > 1.5 × ULN;

          • Triglyceride >500 mg/dL (5.64 mmol/L);

            • Estimated (absolute eGFR) based on the CKD-EPI equation \<60 mL/min;

              • Serum calcitonin level ≥50 ng/L; ⑦ Thyroid-stimulating hormone >6.0 mIU/L or \<0.4 mIU/L;

                ⑧ Blood amylase or blood lipase >2×ULN;

                • (PT)-international normalized ratio (INR) exceeds the upper limit of normal, and the investigator determines the abnormality to be , making it unsuitable for the participant to be enrolled; ⑩ \<110 g/L (male) or \<100 g/L (female); ⑪ Positive test result for any one or more of the following items: surface antigen, antibody, antibody/p24 antigen, or Treponema pallidum antibody;

    Presence of any of the following diseases or medical history prior to screening or randomization:

  2. Participants who currently have or with history of severe diseases involving nervous system, psychiatric system, digestive system, circulatory system, respiratory system, urinary system, etc., or have newly developed diseases before administration of the product, and therefore are deemed by the investigator as unsuitable for participation in this study;
  3. Past history or ultrasound findings during screening period include any of the following conditions: medical history of chronic pancreatitis, acute pancreatitis, cholecystitis, or symptomatic/treatment-requiring gallbladder stones (except for participants who have undergone cholecystectomy but are deemed eligible for enrollment by the investigator);
  4. Participants with a history or family history of thyroid C-cell tumors or multiple endocrine neoplasia type 2;
  5. Participants with a history of metabolic disorders (such as unexplained recurrent hypoglycemia) who are deemed unsuitable for participation in this study upon the evaluation by the investigator;
  6. Presence of endocrine diseases or medical history that may significantly affect weight (e.g., Cushing's syndrome, hypothyroidism, hyperthyroidism, etc., except for hypothyroidism if thyroid hormone replacement dosage has been stabilized for at least 6 months), or obesity due to a single gene mutation or hereditary obesity syndrome, etc.;
  7. Presence of disorders and planned use of systemic therapy or therapy during the study;
  8. Participants with a history of significant gastric emptying abnormalities, severe gastrointestinal disorder, or gastrointestinal surgery (excluding polypectomy, appendicectomy, and haemorrhoid operation) who are deemed unsuitable for participation in this study upon the evaluation by the investigator;
  9. Participants who have undergone surgeries that may affect drug absorption, distribution, metabolism, or excretion, and are deemed unsuitable for enrollment by the investigator;
  10. Participants who are prone to allergic reactions or with allergic constitution (e.g., those allergic to pollen, two or more drugs/foods), or participants with known to any component of the investigational product or similar drugs (Tirzepatide, GLP-1R agonists, or compounds containing GLP-1R agonists); or participants with a history of photosensitivity.
  11. Blood donation and/or blood loss ≥400 mL or bone marrow donation within 3 months prior to screening; or haemoglobinopathy, haemolytic anaemia, or sickle cell anaemia at screening;
  12. Past medical history of moderate to severe depression; or history of suicidal ideation or suicidal behavior; or past medical history of serious psychiatric disorders, e.g., schizophrenia, bipolar affective disorder, etc.; or a score of ≥9 on the Patient Health Questionnaire-9 (PHQ-9) at screening (self-rated by the participant);

    Participants who received any of the following drugs or treatments prior to screening:

  13. Participants who have been previously treated with similar drugs of HS-20094 (Tirzepatide, GLP-1 analogues, or related compounds), and/or those who require the use of DPP-4 inhibitors (drugs affecting GLP-1 levels) during the study;
  14. Any use of drugs or treatments that may cause significant weight gain or loss within 3 months prior to screening:

    ① Use of any GLP-1R-related single/multi-target drug that promotes weight loss, including, but not limited to, GLP-1R agonists, glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonists, glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor (GLP-1R/GIPR) agonists, GLP-1R/GIPR/GCGR agonists, etc.;

    ② Any drug that may cause weight gain, including: systemic glucocorticoid medications (except for short-term use of \<14 days or topical administration, inhalation, intraocular, or nasal administration), tricyclic antidepressants, atypical antipsychotics, and mood stabilizers (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproate, valproate derivatives, lithium salts), etc.;

    ③ Any Chinese herbal medicines, health care products, meal replacements, weight-reducing teas, etc. or similar products for the purpose of weight loss;

    ④ Any approved or unapproved weight-reducing drugs, such as sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, mazindol, phentermine, diethylpropion, lorcaserin, phentermine/topiramate coformulation, naltrexone/bupropion coformulation, etc.;

    ⑤ Any glucose-lowering drugs, such as metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), etc.;

  15. History of bariatric/metabolic surgery within 12 months prior to screening, or participants who have not recovered from any surgery or trauma at screening, or participants who have recovered from gastrointestinal surgery prior to screening that affected gastrointestinal motility;
  16. Participants who have received immunization of any vaccine within four weeks prior to the first dose of the investigational product, or who plan to receive immunization of any vaccine during the study or within 2 weeks after study completion.
  17. Participants who have participated in any other clinical studies and received administration of investigational products within 3 months prior to screening; or the time interval from administration in the previous clinical study is less than 7 half-lives (whichever is longer);

    Participants with any of the following conditions:

  18. Participants with abnormal findings in physical examination, vital signs, clinical laboratory tests, abdominal ultrasound, thyroid color Doppler ultrasound, etc., deemed by the investigator to be clinically significant and assessed as unsuitable for enrollment.
  19. Participants with heart rate (HR) of \<50 beats per minute or >100 beats per minute by 12-lead (ECG) during screening. A retest is allowed, and the participant will be excluded if both tests fail;
  20. Presence of any of the following abnormalities on 12-lead ECG at screening: second or third degree AV block, long syndrome, pre-excitation syndrome, ventricular tachycardia, atrial fibrillation, or QTcF >450 ms in males and >470 ms in females, or any other arrhythmia deemed clinically significant by the investigator. Participants with abnormal QTcF on the first examination should repeat the ECG twice more, and the mean of the three results should be used as the basis for judgment;
  21. History of drug abuse, drug dependence, or illicit drug use within 5 years prior to screening, or positive urine drug screening;
  22. Participants who consumed excessive amounts of tea, coffee, and/or caffeinated beverages (more than 8 cups per day on average, 1 cup = 200 mL) within 3 months prior to screening;
  23. Participants who smoke an average of more than 5 cigarettes per day within the 3 months prior to screening;
  24. Participants who frequently consume alcohol within 3 months prior to screening (i.e., weekly alcohol intake exceeding 14 units, where 1 unit = 14 g of alcohol, equivalent to 360 mL of beer, 45 mL of spirits with alcohol content of 40%, or 150 mL of wine, corresponding to 10 bottles of beer, 500 g of Baijiu, or 3 bottles of red wine per week);
  25. Planned bariatric surgery, acupuncture for weight loss, liposuction, or abdominoplasty during the study; or other planned surgery during the study (except for minor surgery that, in the opinion of the investigator, does not interfere with the study);
  26. Female participants who are in the lactation period within 1 month prior to screening or during the study; or female participants with positive result in pregnancy test;
  27. Participants who have engaged in unprotected sexual intercourse within 14 days prior to study treatment (applicable to female participants only);
  28. Participants with history of needle phobia or blood phobia, or participants assessed by the investigator as having difficulty in blood collection, or participants cannot tolerate blood collection via venipuncture/indwelling needle;
  29. Other participants deemed unsuitable for participating in the study by the investigator or participants who voluntarily withdraw from the study or who are lost to follow-up for personal reasons.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    T1 group

    HS-20094 AI pen administered subcutaneously (SC) once a week.

    Drug: HS-20094 AI pen;

  • Experimental
    T2 group

    HS-20094 MDV pen administered subcutaneously (SC) once a week.

    Drug: HS-20094 MDV pen

Interventions

  • Arm 1: Administered SC The dose is escalated every 4 weeks until the target dose of 15 mg is reached. The dose escalation scheme is as follows: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.

  • The dose is escalated every 4 weeks until the target dose of 15 mg is reached. The dose escalation scheme is as follows: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.

07

What researchers measure

Primary outcomes

  1. To evaluate the bioequivalence of HS-20094 MDV pen and AI pen following multiple doses at 15 mg.

    PK parameters of HS-20094 following multiple doses at 15 mg administered via HS-20094 MDV pen and AI pen: AUC0-168h.

    Time frame: From Day 1 to Day 169

  2. To evaluate the bioequivalence of HS-20094 MDV pen and AI pen following multiple doses at 15 mg.

    PK parameters of HS-20094 following multiple doses at 15 mg administered via HS-20094 MDV pen and AI pen: Cmax

    Time frame: From Day 1 to Day 169

Secondary outcomes

  1. To evaluate the bioequivalence of HS-20094 MDV pen and AI pen following multiple doses at 10 mg

    PK parameters following multiple doses at 10 mg administered via the HS-20094 MDV pen and AI pen: AUC0-168h;

    Time frame: From Day 1 to Day 169

  2. To evaluate the bioequivalence of HS-20094 MDV pen and AI pen following multiple doses at 10 mg

    PK parameters following multiple doses at 10 mg administered via the HS-20094 MDV pen and AI pen: Cmax

    Time frame: From Day 1 to Day 169

  3. To evaluate the safety following administration via the HS-20094 MDV pen and AI pen

    Adverse events

    Time frame: From Day 1 to Day 204

  4. Number of participants with Vital signs

    To evaluate the safety following administration via the HS-20094 MDV pen and AI pen

    Time frame: From Day 1 to Day 204

  5. To evaluate the safety following administration via the HS-20094 MDV pen and AI pen

    Number of participants with Abnormal Laboratory Values

    Time frame: From Day 1 to Day 204

  6. To evaluate the safety following administration via the HS-20094 MDV pen and AI pen

    12-lead ECG, including heart rate, P-R interval, RR interval, QRS, and QTcF

    Time frame: From Day 1 to Day 204

  7. To evaluate the safety following administration via the HS-20094 MDV pen and AI pen

    Physical examination questionnaire includes: general appearance, skin, lymph nodes, head, throat/thyroid, chest, abdomen, musculoskeletal system, nervous system, cardiovascular system, and others.

    Time frame: From Day 1 to Day 204

  8. To evaluate the immunogenicity of HS-20094 MDV pen and AI pen after treatment.

    ADA of HS-20094: ADA positivity rate

    Time frame: Days 1, 29, 57, 85, 106, 141, and 169

  9. To evaluate the immunogenicity of HS-20094 MDV pen and AI pen after treatment.

    ADA of HS-20094: Including ADA titer.

    Time frame: Days 1, 29, 57, 85, 106, 141, and 169

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2026, 9 months after the start.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 9 months is close to that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jul 10, 2025
StartActual
Apr 16, 2025
Primary completionEst.
Feb 4, 2026
CompletionEst.
May 29, 2026
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07057674
Responsible party
Sponsor
First posted
Jul 10, 2025
Start date
Apr 16, 2025
Primary completion
Feb 4, 2026 (estimated)
Completion
May 29, 2026 (estimated)
Last update
Jul 10, 2025

Study contacts

Yu Cao
Contact
caoyu1767@126.com
18661809090

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-20094

Start the discussion